PTC Therapeutics Competitors

PTC Therapeutics (NASDAQ:PTCT) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and BioMarin Pharmaceutical, as provided by MarketBeat.com.

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. BioMarin Pharmaceutical has a consensus target price of $119.8750, suggesting a potential upside of 55.92%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Earnings and Valuation

This table compares PTC Therapeutics and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

BioMarin Pharmaceutical has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

98.6% of BioMarin Pharmaceutical shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats PTC Therapeutics on 10 of the 14 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and GRIFOLS S A/S (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and GRIFOLS S A/S, as provided by MarketBeat.com.

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than GRIFOLS S A/S.

Profitability

This table compares PTC Therapeutics and GRIFOLS S A/S's net margins, return on equity and return on assets.

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, GRIFOLS S A/S has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Earnings and Valuation

This table compares PTC Therapeutics and GRIFOLS S A/S's revenue, earnings per share (EPS) and valuation.

GRIFOLS S A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than GRIFOLS S A/S, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

18.0% of GRIFOLS S A/S shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

GRIFOLS S A/S beats PTC Therapeutics on 8 of the 14 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and Elanco Animal Health, as provided by MarketBeat.com.

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Elanco Animal Health has a consensus target price of $28.50, suggesting a potential downside of 7.56%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than Elanco Animal Health.

Profitability

This table compares PTC Therapeutics and Elanco Animal Health's net margins, return on equity and return on assets.

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Earnings and Valuation

This table compares PTC Therapeutics and Elanco Animal Health's revenue, earnings per share (EPS) and valuation.

Elanco Animal Health has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

98.2% of Elanco Animal Health shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 0.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Elanco Animal Health beats PTC Therapeutics on 7 of the 13 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Myokardia (NASDAQ:MYOK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for PTC Therapeutics and Myokardia, as provided by MarketBeat.com.

PTC Therapeutics currently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Myokardia has a consensus target price of $207.40, suggesting a potential downside of 7.00%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than Myokardia.

Volatility and Risk

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Myokardia has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Myokardia's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares PTC Therapeutics and Myokardia's revenue, earnings per share (EPS) and valuation.

PTC Therapeutics has higher revenue and earnings than Myokardia. Myokardia is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

PTC Therapeutics beats Myokardia on 8 of the 12 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

12.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PTC Therapeutics and Dr. Reddy's Laboratories, as provided by MarketBeat.

PTC Therapeutics presently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Dr. Reddy's Laboratories has a consensus target price of $53.00, suggesting a potential downside of 20.78%. Given PTC Therapeutics' higher possible upside, equities analysts clearly believe PTC Therapeutics is more favorable than Dr. Reddy's Laboratories.

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares PTC Therapeutics and Dr. Reddy's Laboratories' revenue, earnings per share (EPS) and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

92.7% of Sarepta Therapeutics shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PTC Therapeutics and Sarepta Therapeutics, as provided by MarketBeat.

PTC Therapeutics presently has a consensus target price of $61.80, suggesting a potential upside of 18.96%. Sarepta Therapeutics has a consensus target price of $197.8696, suggesting a potential upside of 42.74%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than PTC Therapeutics.

Risk & Volatility

PTC Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares PTC Therapeutics and Sarepta Therapeutics' revenue, earnings per share (EPS) and valuation.

PTC Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sarepta Therapeutics beats PTC Therapeutics on 10 of the 14 factors compared between the two stocks.